Roivant Sciences (ROIV)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ROIV's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Roivant Sciences's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $55M | $32M | $33M | $29M | $8M |
| Net income | -$845M | -$1.0B | $4.3B | -$172M | -$300M |
| Free cash flow | -$695M | -$856M | -$767M | -$844M | -$759M |
| EPS (diluted) | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.54 |
| Operating margin | -2444.8% | -2875.9% | 13746.9% | -3453.3% | -6235.7% |
Where the revenue comes from
Revenue by products, fiscal 2024.
Superinvestors who own ROIV
From each investor's latest 13F filing (what a 13F shows). 7 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Tom Steyer Farallon Capital Management LLC |
Added | $506M | 2.4% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $234M | 0.08% | Q2 2026 |
| Andreas Halvorsen Viking Global Investors |
Trimmed | $222M | 0.63% | Q2 2026 |
| Lee Ainslie Maverick Capital |
Added | $100M | 0.88% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Trimmed | $63M | 0.05% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $48M | 0.11% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
Held | $4M | 0.01% | Q2 2026 |
Insider buying
Open-market purchases by Roivant Sciences's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ROIV trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are Roivant Sciences insiders buying the stock?
No open-market insider purchases of ROIV in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Roivant Sciences?
7 of the superinvestors Investingly tracks hold ROIV in their latest 13F, including Tom Steyer, Cliff Asness, Andreas Halvorsen.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.